Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence
Technology appraisal guidance
Reference number: TA810
Published:
Evidence
Documents containing the evidence that was used to develop the recommendations.